To Investigate the Safety, Pharmacodynamics and Effect on Allergic Reactivity of the Toll-like Receptor 7 (TLR7) Agonist GSK2245035 in Subjects With Respiratory Allergies

NCT01788813 | Completed Phase 2

• 1 other identifier: 116958
• Study Type: interventional
• Target: 42
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to examine the safety and effects on the immune system of treatment with GSK2245035 in subjects who suffer from nasal symptoms caused by an allergy to pollen or perennial allergen, with or without mild asthma. In addition, the effect of treatment with GSK2245035 on the body's allergic response in test situations will be explored. Approximately 28 subjects will receive GSK2245035 (up to 14 subjects each receiving 80 nanograms \[ng\] GSK2245035 and up to 14 subjects each receiving 20 ng GSK2245035) and 14 subjects will receive the dummy drug (placebo) during the study. Assignment of a subject to GSK2245035 or placebo will be done by chance, like flipping a coin. Neither the subjects nor the clinic staff will know whether a subject is being dosed with GSK2245035 or placebo during the course of the study. The study will include (a) Screening phase where the eligibility of subjects for enrolment will be assessed (b) Treatment phase during which subjects will receive either 8 nasal sprays of GSK2245035 80 ng or a matching placebo once weekly for 8 weeks (each dose will be split between the two nostrils). Subjects participating in this study in 2014 will receive a reduced dose of 20 ng i.n. of GSK2245035 once weekly for eight administrations (c) Follow-up period where any GSK2245035 induced changes to the immune system and the effect of treatment on the body's allergic response in test situations will be monitored. The maximum planned study duration for all subjects, including the screening, treatment and follow-up periods, is approximately 180 days.

Conditions

Mild Asthma and Allergic Rhinitis

Keywords

Repeat Dose Safety; Allergic Asthma; Effect on Allergen Reactivity; Allergic Rhinitis; TLR7 Agonist; Pharmacodynamics

Outcome Measures

Primary Outcomes (8)

• Safety assessed by number of subjects with adverse events

  Up to 180 days

• Safety assessed by measurement of body temperature

  The measurement of body temperature with an automatic thermometer placed in the subject's mouth will be performed by the research unit staff when a subject is in the unit and by the individual when a subject is not in the unit

  Up to 180 days

• Safety assessed by lung function measurements

  Spirometry will be performed at screening and Peak Expiratory Flow will be measured at all other planned time points

  Up to 180 days

• Safety assessed by measurement of clinical laboratory parameters

  Hematology, clinical chemistry, urinalysis and additional parameters to be tested

  Up to 180 days

• Nasal examination for assessment of nasal tolerability

  Visual examination of the nose will be done to assess the color of mucosa, degree of turbinate swelling, presence/description of any secretion, presence/absence of infection, post-nasal drip, crusting, signs of bleeding and any other signs of irritancy

  Up to 180 days

• Nasal symptoms monitoring for assessment of nasal tolerability

  Nasal tolerability will be assessed using a Visual analogue scale scoring system. Subjects will be asked to respond to various statements of a questionnaire by placing a small vertical mark on a horizontal line, 10 centimeters in length, with a statement placed at each end of the line. Nasal symptoms of rhinorrhea, blockage, itchiness, soreness or dryness and modification of the sense of taste/smell will be assessed

  Up to 7 weeks (Dosing Visits 1 to 8)

• Measurement of TLR7-induced blood Pharmacodynamic (PD) biomarkers, including TLR7-induced cytokines

  Blood samples will be collected to measure levels of TLR7-induced soluble biomarkers and/or allergic blood biomarkers, including but not limited to immunoglobulins

  Up to 180 days (Screening Allergen Challenge Visit 2, Dosing Visits 1 and 8, Follow-up Allergen Challenge Visits

• Measurement of TLR7-induced nasal PD biomarkers, including but not limited to Interferon gamma-induced protein 10 (IP-10) measurement in nasal fluid

  During allergen challenge visits, nasal lavage samples will be collected from one nostril only; nasal filters will be inserted in the other nostril and will remain there for 5 minutes

  Up to 180 days (Screening Allergen Challenge Visit 2, Dosing Visits 1 and 8, Follow-up Allergen Challenge Visits

Study Arms (2)

GSK2245035 Arm

EXPERIMENTAL

Subjects participating prior to 2014 will receive i.n GSK2245035 80 ng once weekly for 8 weeks (each dose will be split between the two nostrils). Subjects participating in 2014 will receive i.n GSK2245035 20 ng once weekly for 8 weeks (each dose will be split between the two nostrils).

Drug: GSK2245035

Placebo Arm

PLACEBO COMPARATOR

Subjects will receive i.n placebo once weekly for 8 weeks (each dose will be split between the two nostrils)

Drug: Placebo

Interventions

GSK2245035 DRUG

Nasal spray solution, to be given intranasal, 80 ng/20 ng once weekly for 8 weeks

GSK2245035 Arm

Placebo DRUG

Nasal Spray Solution, to be given intranasal, once weekly for 8 weeks

Placebo Arm

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Good general health, as determined by a responsible and experienced physician, based on a medical evaluation, including medical history, physical examination, laboratory tests and cardiac monitoring. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the investigator agrees that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures
• Body weight \>=45 kilograms (kg)
• History of symptomatic pollen- or perennial allergen- driven allergic rhinitis with or without mild asthma (with a clear link between exposure to allergen and development of symptoms) for more than 2 years
• Positive skin allergy test (wheal \>=3 mm\[millimeters\]) or serum allergen-specific Immunoglobulin E (IgE) (\>=class 2) for perennial allergens and/or pollen allergens, relevant to the area of the research unit, within a year from the study start
• Positive screening nasal allergen challenge, defined by a Total nasal symptoms score (TNSS) response of \>=5 (on a 12 point scale) and a decrease in Peak Nasal Inspiratory Flow (PNIF) of \>30%
• Males and non-pregnant or non-lactating females between 18 and 65 years of age inclusive at the time of signing the consent form
• A female subject is eligible to participate if she is of non-childbearing potential, defined as pre-menopausal females with a documented tubal ligation or hysterectomy, or postmenopausal, defined as 12 months of spontaneous amenorrhea (in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) \>40 million international units (MIU)/mL and estradiol \<40 picogram (pg)/mL (\<147 picomoles (pmol)/liter (L) is confirmatory). Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods with a failure rate of \<1% if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment. For most forms of HRT, at least 2-4 weeks should elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method
• A female subject is eligible to participate if she is of child-bearing potential and has a negative early pregnancy test at screening, confirmed menses and/or a negative early pregnancy test within 10 days prior to the first dosing visit, a negative early pregnancy test before each dosing and agrees: to use one of the required contraception methods with a failure rate of \<1% starting at least 2 weeks prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point. The subject must agree to use contraception until four days after the last dosing; or has only same-sex partners, when this is her preferred and usual lifestyle
• Male subjects with female partners of child-bearing potential must agree to use one of the contraception methods: Condom plus partner use of a required highly effective contraceptive (with a failure rate of \<1%); or Abstinence, defined as sexual inactivity consistent with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. This criterion must be followed from the time of the first dose of study medication until four days after the last dosing

You may not qualify if:

• CRITERIA BASED UPON MEDICAL HISTORIES
• History of immunological disorders or other diseases (including, but not limited to, malignancy, cardiovascular, gastro-intestinal, hepatic, renal, hematological, neurological, endocrine or pulmonary disease) that in the opinion of the investigator and GlaxoSmithKline (GSK) medical monitor may pose additional risk factors
• Nasal conditions that according to the opinion of the investigator may affect the outcome of the study, i.e. nasal septal perforation, nasal polyps, other nasal malformations or history of frequent nosebleeds
• Respiratory tract infection within 4 weeks prior to the first dosing
• History of regular alcohol consumption within 6 months of the study defined as: an average weekly intake of \>21 drinks for males or \>12 drinks for females. One drink is equivalent to 12 grams (g) of alcohol: 12 ounces (360 mL) of beer, 5 ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled spirits
• History of drug or other allergy that, in the opinion of the investigator or GSK medical monitor, contraindicates participation in this study
• Serious asthma exacerbation requiring hospital visit and/ or treatment with oral steroids or high doses of inhaled steroids within 6 weeks prior to screening
• Subjects with a history of treatment with allergen-specific immunotherapy within the past 5 years are excluded. (Subjects who received incomplete treatment with allergen-specific immunotherapy more than 5 years ago may be included at the discretion of the investigator and GSK Medical Monitor)
• Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days prior to first dosing and throughout the treatment and follow-up period unless in the opinion of the investigator and/or GSK medical monitor the medication will not interfere with the study procedures or compromise subject safety. Acetaminophen is an exception and will be permitted at daily doses of up to 2 g from screening to follow-up. Approved contraceptives and pre-approved medications as specified in the protocol are also exempt
• Subjects using steroid treatment for allergic rhinitis and/or asthma may participate in the study if they can remain free of medication throughout the treatment and follow-up period starting from the following periods of time prior to screening: Nasal steroids-4 weeks, Oral steroids-12 weeks, Inhaled steroids-4 weeks
• Subjects using other medications for their allergic rhinitis and/or asthma on an as needed basis may participate in the study if they can abstain from: Xanthines (including theophylline, but not including caffeine), anticholinergics, cromoglycates, leukotriene antagonists, 5-lipoxygenase inhibitors and long-acting inhaled beta-agonists from 1 week prior to screening and throughout the treatment and follow-up period; Nasal antihistamines-48 hours prior each visit; Oral antihistamines-76 hours prior each visit; Nasal decongestants-24 hours prior each visit; Oral decongestants-24 hours prior each visit; Short acting inhaled beta-agonists-48 hours prior each visit
• CRITERIA BASED UPON DIAGNOSTIC ASSESSMENTS
• A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening
• A positive test for Human Immunodeficiency Virus (HIV) antibody
• A positive screening or pre-dose drug/alcohol screen, with the following exceptions: (a) Subjects with positive results at the initial drug screening are excluded unless they have previously disclosed the use of a prescription drug that could cause a positive drug screen that according to the opinion of the Investigator and GSK Medical Monitor will not pose any safety risks to the subject and will not compromise the study (b) Subjects with a positive marijuana (THC) screen may be entered into the study at the investigator's discretion but all pre-dose drug screens must be negative (c) Subjects with a positive alcohol screen may have this test repeated at a subsequent screening visit but all pre-dose alcohol screens must be negative.

Sponsors & Collaborators

• GlaxoSmithKline: lead

Study Sites (1)

GSK Investigational Site

Kingston, Ontario, K7L 2V7, Canada

Location

MeSH Terms

Conditions

Rhinitis, Allergic

Interventions

GSK2245035

Condition Hierarchy (Ancestors)

Rhinitis; Nose Diseases; Respiratory Tract Diseases; Respiratory Hypersensitivity; Otorhinolaryngologic Diseases; Hypersensitivity, Immediate; Hypersensitivity; Immune System Diseases

Study Officials

• GSK Clinical Trials

  GlaxoSmithKline

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 7, 2013
• First Posted: February 11, 2013
• Study Start: March 1, 2013
• Primary Completion: August 1, 2014
• Study Completion: August 1, 2014
• Last Updated: October 20, 2014

Record last verified: 2014-08

Locations

CA (1)